Anti-MCP1/CCL2 Antibody Picoband®

Monocyte chemoattractant protein-1 (MCP-1), a member of the chemokine (chemotactic cytokine) family, is a potent monocyte agonist that is upregulated by oxidized lipids. MCP-1 is also known as CCL2, SCYA2, MCAF. MCAF is a member of family of factors involved in immune and inflammatory responses. The amino acid sequence deduced from the nucleotide sequence reveals the primary structure of the MCAF precursor to be composed of a putative signal peptide sequence of 23 amino acid residues and a mature MCAF sequence of 76 amino acid residues. MCP-1 plays a unique and crucial role in the initiation of atherosclerosis and may provide a new therapeutic target in this disorder. Human MCP-1 is a 8.7KDa non-glycoprotein, consisting of 99 amino acids in precursor form and 76 amino acids in mature form.

C-C motif chemokine 2; HC11; Monocyte chemoattractant protein 1; Monocyte chemotactic and activating factor; MCAF; Monocyte chemotactic protein 1; MCP-1; Monocyte secretory protein JE; Small-inducible cytokine A2; CCL2; MCP1, SCYA2

E. coli-derived human MCP-1 recombinant protein (Position: Q24-T99) . Human MCP-1 shares 60.9% and 59.4% amino acid (aa) sequence identity with mouse and rat MCP-1, respectively.

Synthesized in liver and selectively concentrated in bone matrix. Secreted in plasma. It is also found in dentin in much higher quantities than other plasma proteins.

Angiogenesis, Atherosclerosis, Cancer, Cancer Metabolism, Cardiovascular, Chemokines, Heart Disease, Immunology, Innate Immunity, Invasion/Microenvironment, Metabolism, Metabolism Processes, Pathways and Processes, Response To Hypoxia, Vascular Inflammation

Chemotactic factor that attracts monocytes and basophils but not neutrophils or eosinophils. Augments monocyte anti-tumor activity. Has been implicated in the pathogenesis of diseases characterized by monocytic infiltrates, like psoriasis, rheumatoid arthritis or atherosclerosis. May be involved in the recruitment of monocytes into the arterial wall during the disease process of atherosclerosis.

1. Furutani, Y.; Nomura, H.; Notake, M.; Oyamada, Y.; Fukui, T.; Yamada, M.; Larsen, C. G.; Oppenheim, J. J.; Matsushima, K. Cloning and sequencing of the cDNA for human monocyte chemotactic and activating factor (MCAF) . Biochem. Biophys. 2. Gosling, J.; Slaymaker, S.; Gu, L.; Tseng, S.; Zlot, C. H.; Young, S. G.; Rollins, B. J.; Charo, I. F. MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B. J. Clin. Invest. 103: 773-778, 1999. 3. Gu, L.; Okaka, Y.; Clinton, S. K.; Gerard, C.; Sukhova, G. K.; Libby, P.; Rollins, B. J. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low absorbance lipoprotein receptor-deficient mice.

Store at -20°C for one year from date of receipt. After reconstitution, at 4°C for one month. It can also be aliquotted and stored frozen at -20°C for six months. Avoid repeated freeze-thaw cycles.